Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.
Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at tackling diseases linked to latent or persistent viral reservoirs. The company employs advanced nucleases, including CRISPR/Cas9 technology, to precisely target and disrupt viral DNA. Established in 2014 and headquartered in South San Francisco, California, Agenovir operates as a subsidiary of Vir Biotechnology, Inc. Its innovative approach seeks to create a new class of nuclease-based antiviral therapeutics that can effectively eliminate pathogenic viral genomes, thereby providing healthcare providers with tools to treat patients suffering from severe and persistent viral infections.
Humabs BioMed
Acquisition in 2017
Humabs BioMed SA, founded in 2004 and based in Bellinzona, Switzerland, specializes in developing human monoclonal antibody platforms aimed at treating infectious and inflammatory diseases. The company focuses on generating innovative therapies through partnerships with pharmaceutical firms and universities. Currently, Humabs has two clinical-stage programs: one in collaboration with MedImmune, a subsidiary of AstraZeneca, which involves an antibody targeting the influenza A virus that has shown efficacy against various subtypes, and another partnered with Novartis, which is in phase 2 development for an undisclosed target. Humabs' antibody technologies are designed to elicit therapeutic immune responses to combat serious infections, addressing gaps in treatment for both common and rare diseases.
TomegaVax
Acquisition in 2017
TomegaVax Inc. is an immunotherapy company that specializes in the development of a novel vaccine technology platform aimed at addressing chronic and recurring viral infections. The company's focus is on creating vaccines and immunotherapies for significant health challenges such as Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV), and Herpes Simplex Virus (HSV). TomegaVax's platform is designed to provide continuous low-level antigen presentation, which helps to maintain an active T-cell-mediated immune response. This innovative approach allows for the potential treatment of previously difficult-to-treat viral infections, offering new hope for patients in need of effective therapeutic options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.